Summit Therapeutics
SMMT
100 hedge funds and large institutions have $87.7M invested in Summit Therapeutics in 2023 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 25 closing their positions.
137% more capital invested
Capital invested by funds: $37.1M → $87.7M (+$50.7M)
40% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 25
10% more funds holding
Funds holding: 91 → 100 (+9)
1.99% more ownership
Funds ownership: 3.02% → 5.01% (+2%)
0% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 24
15% less call options, than puts
Call options by funds: $312K | Put options by funds: $366K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.46M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.89M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.9M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.39M |
| 2 |
Millennium Management
New York
|
-$1.44M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.4M |
| 4 |
Jane Street
New York
|
-$718K |
| 5 |
HF
HRT Financial
New York
|
-$696K |
SMMT Hedge Fund Activity: Q2 2023 in Review
100 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2023, worth a combined $87.7M — up 137% from $37.1M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new SMMT positions and 25 closed out — a net gain of 10 holders — while 24 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $12.6M. The largest seller was Susquehanna International Group, cutting an estimated $2.39M.
- 100 institutional investors held Summit Therapeutics (SMMT) as of Q2 2023, up from 91 in Q1 2023.
- Funds reported $87.7M of Summit Therapeutics stock for Q2 2023, up 137% quarter-over-quarter.
- 35 funds opened new Summit Therapeutics positions in Q2 2023 and 25 closed out, a net change of +10 holders.
- The largest Summit Therapeutics buyer in Q2 2023 was BlackRock, an estimated $12.6M added.
- The largest Summit Therapeutics seller in Q2 2023 was Susquehanna International Group, an estimated $2.39M sold.
Based on aggregated 13F filings for Q2 2023.